Add like
Add dislike
Add to saved papers

High toxicity of Bi(OH) 3 and α-Bi 2 O 3 nanoparticles towards malignant 9L and MCF-7 cells.

Here we report the extreme toxicity in vitro of Bi(OH)3 and α-Bi2 O3 nanoparticles (NPs), obtained through a facile synthesis with an average single particle size of 6-10 nm, tested on malignant gliosarcoma 9L and MCF-7 human breast cancer cells. For both nanomaterials, clonogenic assays reveal a mortality of over 90% in 9L and MCF-7 cells for a concentration of 50 μg/mL after incubation for 24 h. Moreover, the NPs show a significant mortality of up to 60% in the malignant cells at the very low concentration of 6.25 μg/mL. In contrast, at the same concentration, the nanomaterials exhibit no noticeable mortality towards normal Madin-Darby canine kidney cells. The internalisation of the NPs was demonstrated using flow cytometry and confocal microscopy was used to investigate when the loss of cell viability starts. The NPs show a faster cell death in 9L cells compared with MCF-7 cells, demonstrated via the identification of apoptosis through increased sub G1 levels after 24 h of NP incubation. Cleavage is identified as the main apoptotic nuclear morphology in 9L, which suggests the presence of reactive oxygen species.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app